Amundi Reduces Stock Holdings in Moderna, Inc. $MRNA

Moderna climbs 8% as volatile trading continues (MRNA:NASDAQ)

Moderna (MRNA) stock jumps 8% as Phase 3 melanoma mRNA cancer therapy with Merck sparks rally; see key stats, analyst views, and what to watch—read now.

Moderna Rallies 8% on 2026 Melt-Up Momentum Even While BioNTech and Merck Stay Flat

Moderna (NASDAQ:MRNA) stock is up 8% to $147.37 in Friday morning trading, a sharp single-name move on a session when biotech as a group is quiet and broader U.S. equities are only modestly higher. The SPDR S&P Biotech ETF (NYSEARCA:XBI) is down 0.1%, so the sector benchmark isn’t providing any lift for Moderna. Broad-market context […]

Amundi Reduces Stock Holdings in Moderna, Inc. $MRNA

Amundi lowered its stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 1.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 888,779 shares of the company's stock after selling 16,044 sh